Anacor Pharmaceuticals Inc (ANAC) financial statements (2020 and earlier)

Company profile

Business Address 1020 E. MEADOW CIRCLE
PALO ALTO, CA 94303
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 14214615046
Cash and cash equivalents 541611510
Short-term investments 881303635
Restricted cash and investments 12  
Receivables 18611
Inventory, net of allowances, customer advances and progress billings 33
Inventory 33  
Prepaid expense and other current assets3
Other undisclosed current assets 754 
Total current assets: 17016115549
Noncurrent Assets
Property, plant and equipment 2212
Long-term investments and receivables  4212 
Long-term investments  4212 
Restricted cash and investments 2230
Other noncurrent assets 220
Prepaid expense and other noncurrent assets0
Other undisclosed noncurrent assets  1  
Total noncurrent assets: 648172
TOTAL ASSETS: 17620917251
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 1814105
Accounts payable 6553
Accrued liabilities 54  
Employee-related liabilities 6532
Taxes payable   2 
Debt    10
Deferred revenue and credits 5513
Deferred tax liabilities  1  
Other liabilities  1  
Other undisclosed current liabilities 7857
Total current liabilities: 30291625
Noncurrent Liabilities
Long-term debt and lease obligation 61602816
Long-term debt, excluding current maturities 61602816
Liabilities, other than long-term debt 333725
Deferred revenue and credits 333725
Total noncurrent liabilities: 94973021
Total liabilities: 1241254646
Temporary equity, carrying amount 055 
Stockholders' equity
Stockholders' equity attributable to parent 52791215
Common stock 0000
Additional paid in capital 331297252220
Accumulated other comprehensive income (loss) 0(0)(0)0
Accumulated deficit (279)(218)(130)(215)
Total stockholders' equity: 52791215
TOTAL LIABILITIES AND EQUITY: 17620917251

Income statement (P&L) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
 82211711
Cost of revenue
(Cost of Goods and Services Sold)
 (4)(1)  
Gross profit: 78201711
Operating expenses (139)(111)75(64)
Other undisclosed operating income 41  
Operating income (loss): (56)(91)93(53)
Nonoperating income (expense) 10(1)0
Investment income, nonoperating 1000
Other nonoperating expense  (0)(1)(0)
Interest and debt expense (6)(7)(5)(3)
Income (loss) from continuing operations before income taxes: (61)(97)86(56)
Income tax expense (benefit)  10(2) 
Net income (loss) available to common stockholders, diluted: (61)(87)85(56)

Comprehensive Income ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net income (loss): (61)(87)85(56)
Comprehensive income (loss): (61)(87)85(56)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 0(0)(0)0
Comprehensive income (loss), net of tax, attributable to parent: (61)(87)85(56)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: